financetom
Business
financetom
/
Business
/
Uber Spices Up Taiwan's Food Delivery Scene With $950M foodpanda Deal: What's On The Menu?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Uber Spices Up Taiwan's Food Delivery Scene With $950M foodpanda Deal: What's On The Menu?
May 14, 2024 3:19 AM

Uber Technologies, Inc ( UBER ). and Delivery Hero SE have struck a deal, with Uber ( UBER ) set to acquire Delivery Hero’s foodpanda delivery arm in Taiwan for $950 million in cash.

Separately, the companies have also agreed for Uber ( UBER ) to purchase $300 million in newly issued ordinary shares of Delivery Hero.

The transaction is pending regulatory approval and customary closing conditions, slated for the first half of 2025. 

Until closing, Delivery Hero will maintain foodpanda Taiwan’s operations, assuring customers and vendors of uninterrupted service. 

Post-acquisition, Uber Eats will absorb foodpanda’s local clientele, merchants, and delivery partners.

Uber’s existing presence in Taiwan positions it favorably to leverage Delivery Hero’s groundwork and enhance user experiences. 

Niklas Östberg, Delivery Hero’s CEO, expressed confidence in the deal, affirming the move’s potential for foodpanda’s growth in Taiwan.

The merger aims to amalgamate Uber’s operational proficiency with foodpanda’s extensive reach and local affiliations, offering consumers broader options in cuisine and pricing. 

Also Read: Tesla Vs. Uber ( UBER ): If You Invested $1,000 Each In These Companies In 2022, Here’s How Much You Would Have Now

This synergy promises improved services, increased orders for merchants, and enhanced earning prospects for delivery partners.

Pierre-Dimitri Gore-Coty, Uber’s Senior Vice President of Delivery, said, “Taiwan is a fiercely competitive market, where online food delivery platforms today still represent just a small part of the food delivery landscape.”

“We’re so excited about the opportunity to deliver even greater convenience and value that this transaction would unlock in the years ahead.” 

Upon completion, this acquisition would mark one of Taiwan’s largest international deals, signaling Uber’s confidence in Taiwan’s investment climate.

Price Action: UBER ( UBER ) shares closed lower by 1.45% at $66.02 on Monday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ocular Therapeutix Q4 Net Loss Narrows, Revenue Rises
Ocular Therapeutix Q4 Net Loss Narrows, Revenue Rises
Mar 3, 2025
07:21 AM EST, 03/03/2025 (MT Newswires) -- Ocular Therapeutix ( OCUL ) reported Monday a Q4 net loss of $0.29 per diluted share, narrower than its loss of $0.35 per share a year earlier. Analysts polled by FactSet expected a loss of $0.25. Revenue for the quarter ended Dec. 31 was $17.1 million, up from $14.8 million a year earlier....
Richards Packaging Income Fund Buys National Dental Inc. and HL Production SA
Richards Packaging Income Fund Buys National Dental Inc. and HL Production SA
Mar 3, 2025
07:20 AM EST, 03/03/2025 (MT Newswires) -- Richards Packaging Income Fund (RPI-UN.TO) over the weekend announced two strategic acquisitions to add to its healthcare line up. The Fund, through its subsidiary, Clarion Medical Technologies Inc., has acquired all of the outstanding shares of National Dental Inc., a Canadian provider of high-tech laser and diagnostic devices to the dental care industry....
Biogen's Alzheimer's Treatment Lecanemab Denied Approval in Australia
Biogen's Alzheimer's Treatment Lecanemab Denied Approval in Australia
Mar 3, 2025
07:20 AM EST, 03/03/2025 (MT Newswires) -- Biogen (BIIB) said Monday the Therapeutic Goods Administration of Australia has reaffirmed its earlier decision to reject lecanemab as a treatment for early Alzheimer's disease. The TGA suggested restricting the drug's use to ApoE4 noncarriers due to safety risks, but Biogen's revised proposals were declined as well, the company said. Biogen said the...
N-able's Q4 Non-GAAP Earnings Decline, Revenue Increases; Q1, 2025 Revenue Outlook Issued
N-able's Q4 Non-GAAP Earnings Decline, Revenue Increases; Q1, 2025 Revenue Outlook Issued
Mar 3, 2025
07:18 AM EST, 03/03/2025 (MT Newswires) -- N-able (NABL) reported Q4 non-GAAP earnings Monday of $0.10 per diluted share, down from $0.11 a year earlier. Analysts polled by FactSet expected $0.08. Revenue for the quarter ended Dec. 31 was $116.5 million, compared with $108.4 million a year earlier. Analysts polled by FactSet expected $114 million. The company said it expects...
Copyright 2023-2026 - www.financetom.com All Rights Reserved